Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new class of glucose-lowering agents which have changed the landscape of diabetes therapy, due to their remarkable cardiorenal protective properties. The attack of severe acute respiratory syndrome coronavirus 2 on the heart and kidneys share...

Full description

Saved in:
Bibliographic Details
Published in:Int J Clin Pharm
Main Authors: Koufakis, Theocharis, Pavlidis, Antonis N., Metallidis, Symeon, Kotsa, Kalliopi
Format: Artigo
Language:Inglês
Published: Springer International Publishing 2021
Subjects:
Commentary
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7942520/
https://ncbi.nlm.nih.gov/pubmed/33751323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11096-021-01256-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items